| Resolution Minerals Ltd (RML) ORDINARY FULLY PAID |
Materials |
$136 |
Notice of ceasing to be a substantial holder
|
30 Jul 2025 9:48AM |
$0.079 |
$0.065 |
fallen by
17.72%
|
|
| Hejaz Sukuk Active ETF (Managed Fund) (SKUK) |
Financials |
$5 |
Distribution payment date update - June 2025
|
30 Jul 2025 9:48AM |
$1.040 |
$1.005 |
fallen by
3.37%
|
|
| Nickel Industries Limited (NIC) ORDINARY FULLY PAID |
Materials |
$4,624 |
Quarterly Activities Report
|
30 Jul 2025 9:47AM |
$0.770 |
$1.065 |
risen by
38.31%
|
|
NIC - Price-sensitive ASX Announcement
Full Release
Key Points
- Nickel Industries reported a 4% decrease in RKEF nickel production for the June 2025 quarter compared to the previous quarter.
- The company's cash costs increased by 5% due to maintenance and higher electricity costs.
- Hengjaya Mine achieved record sales of 3,021,678 tonnes, with an EBITDA of US$41.4 million.
- The company continues to progress the Sampala Project, with significant exploration drilling completed.
- Nickel Industries' trading division experienced a significant decrease in EBITDA due to lower sales.
- The company is moving forward with its environmental study for increasing its sales quota.
- Nickel Industries plans to increase its interest in the Excelsior Nickel Cobalt HPAL project to 55% by April 2026.
- Nickel Industries received dividends from its various projects, contributing to its financial stability.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nickel Industries Limited (NIC) ORDINARY FULLY PAID |
Materials |
$4,624 |
Quarterly Activities Report
|
30 Jul 2025 9:47AM |
$0.770 |
$1.065 |
risen by
38.31%
|
|
NIC - Price-sensitive ASX Announcement
Full Release
Key Points
- Nickel Industries Limited holds an 80% indirect interest in RKEF operations and a 10% indirect interest in Huayue Nickel Cobalt.
- RKEF production in Q2 2025 was 30,463 tonnes of nickel, a 4% decrease due to kiln realignment.
- Cash costs for RKEF rose by 5% due to maintenance and electricity costs.
- Huayue Nickel Cobalt's attributable production was 2,075 tonnes of nickel and 188 tonnes of cobalt.
- Hengjaya Mine production increased by 5% to 5,923,539 wmt, with a record sales volume of 3,021,678 tonnes.
- Adjusted EBITDA for RKEF dropped by 24% while mining adjusted EBITDA increased by 33% due to higher nickel prices.
- Expenditure on exploration at Hengjaya Mine was US$0.2m, while Sampala and Siduarsi projects had total expenditures of US$2.5m and US$0.2m respectively.
- Nickel Industries is advancing the ENC HPAL smelter and expects to increase its interest to 55% by April 1, 2026.
- The company published its 2024 Sustainability Report, marking progress towards IFRS Sustainability Disclosure Standards.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Titan Minerals Limited (TTM) ORDINARY FULLY PAID |
Materials |
$239 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jul 2025 9:47AM |
$0.300 |
$0.830 |
risen by
176.67%
|
|
TTM - Price-sensitive ASX Announcement
Full Release
Key Points
- Dynasty Gold Project advanced with ongoing drilling and multiple high-grade assay results reported.
- Environmental, social, and permitting initiatives progressed for project advancement.
- Geological mapping and soil sampling completed to inform further exploration.
- Additional drilling planned for 2023 to expand resource understanding.
- Appendix 5B shows cash flows, including exploration and administrative outflows.
- Successful capital raising activities strengthened financial position.
- Focus remains on sustainable asset growth and stakeholder engagement in Ecuador.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nido Education Limited (NDO) ORDINARY FULLY PAID |
Consumer Discretionary |
$82 |
Appointment of Executive Director - Adam Lai
|
30 Jul 2025 9:47AM |
$0.670 |
$0.360 |
fallen by
46.27%
|
|
| Syntara Limited (SNT) ORDINARY FULLY PAID |
Health Care |
$47 |
Quarterly Shareholder Report
|
30 Jul 2025 9:47AM |
$0.060 |
$0.029 |
fallen by
51.67%
|
|
SNT - Price-sensitive ASX Announcement
Full Release
Key Points
- Syntara Limited provided an update on operational and financial performance for the quarter.
- Key projects and initiatives progressed as planned, with a focus on technological innovation.
- The company invested in infrastructure and product development to maintain competitive advantage.
- Financial results indicate growth in revenue streams and prudent cost management.
- Management discussed market trends, regulatory challenges, and risk mitigation strategies.
- Shareholder value enhancement remains a primary focus through both organic and strategic initiatives.
- Forward-looking statements highlight growth opportunities and ongoing strategic priorities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Transurban Group (TCL) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Industrials |
$43,870 |
Distribution Reinvestment Plan
|
30 Jul 2025 9:47AM |
$13.690 |
$14.060 |
risen by
2.70%
|
|
| Aspermont Limited (ASP) ORDINARY FULLY PAID |
Communication Services |
$22 |
Q3 FY25 Trading Update
|
30 Jul 2025 9:46AM |
$0.005 |
$1.900 |
risen by
37,900%
|
|
ASP - Price-sensitive ASX Announcement
Full Release
Key Points
- Aspermont reported continued revenue growth in Q3 FY25.
- Strong performance in core digital publishing and premium subscriptions.
- Annual recurring revenue (ARR) increased significantly year-on-year.
- Expansion of data, events, and new business service offerings.
- Ongoing investment in digital transformation and technology.
- Focus on client engagement and operational efficiency.
- Robust sales pipeline and confidence in meeting FY25 targets.
- Management highlights sustained growth and margin enhancement opportunities.
- Revenue diversification initiatives progressing according to plan.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Beonic Ltd (BEO) ORDINARY FULLY PAID |
Information Technology |
$7 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jul 2025 9:46AM |
$0.320 |
$0.100 |
fallen by
68.75%
|
|
BEO - Price-sensitive ASX Announcement
Full Release
Key Points
- Beonic Ltd (formerly BEO) released its Quarterly Activities and Appendix 4C Cash Flow Report for the quarter ended 30 June 2023.
- Significant contract wins and expansions, especially in North America.
- Successful launch and deployment of Beonic Analytics platform with positive market response.
- Strong focus on product development and innovation.
- Operating cash flow included receipts from customers and outlays for R&D, staff, and administration.
- Company is focused on operational efficiencies and identifying new growth opportunities.
- Financial position remains robust, supporting ongoing and future activities.
- Report includes details of cash flows, investments, and funding activities.
- Board provided assurances regarding continued solvency and ability to fund operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Arizona Lithium Limited (AZL) ORDINARY FULLY PAID |
Materials |
- |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jul 2025 9:46AM |
$0.008 |
$0.007 |
fallen by
12.50%
|
|
AZL - Price-sensitive ASX Announcement
Full Release
Key Points
- During the quarter, Arizona Lithium advanced the Prairie Lithium Project with drilling, sampling, and pilot plant testing.
- The Big Sandy Lithium Project in Arizona progressed with further technical studies and regulatory engagement.
- The company is focused on progressing both assets towards commercial lithium production.
- Cash outflows were primarily attributed to exploration, evaluation, and development activities.
- The Appendix 5B cash flow report details the financial position, with a strong cash balance maintained.
- Discussions and cooperation with local communities and regulatory authorities continued.
- The company’s strategic focus remains on advancing its lithium assets in Canada and the USA.
- Arizona Lithium achieved significant milestones in resource delineation and pilot-scale processing.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cynata Therapeutics Limited (CYP) ORDINARY FULLY PAID |
Health Care |
$77 |
June 2025 Quarterly Activity Report and Appendix 4C
|
30 Jul 2025 9:45AM |
$0.175 |
$0.323 |
risen by
84.29%
|
|
CYP - Price-sensitive ASX Announcement
Full Release
Key Points
- Cynata Therapeutics Limited provided a Quarterly Activity Report for June 2025.
- Ongoing progress of Cymerus™ MSC technology in clinical trials, especially Phase 3 osteoarthritis study.
- Stable financial position and details regarding operating cash flows for the reported quarter.
- Continued patient recruitment and trial advancements for regenerative medicine products.
- Engagement with regulatory authorities and updates on partnership discussions.
- Emphasis on commercialisation strategies and next steps in development pipeline.
- Focus on maintaining momentum in clinical programs and achieving planned milestones.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AdAlta Limited (1AD) ORDINARY FULLY PAID |
Health Care |
$13 |
1AD Investor Presentation
|
30 Jul 2025 9:45AM |
$0.002 |
$0.005 |
risen by
150%
|
|
| Sequoia Financial Group Ltd (SEQ) ORDINARY FULLY PAID |
Financials |
$25 |
Response to ASX Price Query
|
30 Jul 2025 9:45AM |
$0.240 |
$0.200 |
fallen by
16.67%
|
|
SEQ - Price-sensitive ASX Announcement
Full Release
Key Points
- SEQ received a price and volume query from the ASX regarding unusual trading activity.
- The company confirmed it is not aware of any unannounced information that could explain the change.
- There are no pending or undisclosed matters requiring announcement under ASX Listing Rule 3.1.
- SEQ asserts that it is in compliance with its continuous disclosure obligations.
- The company secretary formally responded to the ASX to clarify the situation.
- SEQ assured the ASX and market participants of its transparency and adherence to regulations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ALS Limited (ALQ) ORDINARY FULLY PAID |
Industrials |
$10,841 |
Retirement of Director
|
30 Jul 2025 9:45AM |
$18.180 |
$21.360 |
risen by
17.49%
|
|
| Nido Education Limited (NDO) ORDINARY FULLY PAID |
Consumer Discretionary |
$82 |
2025 Half Year Results Investor Briefing and buy-back update
|
30 Jul 2025 9:44AM |
$0.670 |
$0.360 |
fallen by
46.27%
|
|
| CurveBeam AI Limited (CVB) ORDINARY FULLY PAID |
Health Care |
$29 |
Investor Presentation - Q4 FY25 Quarterly Update
|
30 Jul 2025 9:44AM |
$0.078 |
$0.060 |
fallen by
23.08%
|
|
CVB - Price-sensitive ASX Announcement
Full Release
Key Points
- CurveBeam AI Limited delivered its Q4 FY25 Investor Presentation on May 8, 2024.
- The company specializes in AI-powered orthopedic imaging solutions.
- Highlights include successful product developments, clinical research milestones, and leadership team expansion.
- The company expanded its commercial footprint in the U.S. and Europe.
- Financial results reflect revenue growth, margin improvement, and positive operating trends.
- Several AI-enabled product launches are in the pipeline, supported by clinical and regulatory progress.
- Ongoing focus on innovation and market leadership in musculoskeletal health imaging.
- Strategic priorities include continued U.S. expansion, operational efficiency, and leveraging AI to address clinical needs.
- Strong commitment to clinical validation and regulatory compliance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Webjet Group Limited (WJL) ORDINARY FULLY PAID |
Consumer Discretionary |
$206 |
Change in substantial holding
|
30 Jul 2025 9:43AM |
$0.910 |
$0.525 |
fallen by
42.31%
|
|
| identitii Limited (ID8) ORDINARY FULLY PAID |
Information Technology |
$6 |
Refinancing of Corporate Funding Arrangements
|
30 Jul 2025 9:42AM |
$0.006 |
$0.006 |
fallen by
0%
|
|
ID8 - Price-sensitive ASX Announcement
Full Release
Key Points
- identitii Limited has refinanced its existing corporate funding arrangements.
- The previous facility with PURE Asset Management has been replaced.
- A new secured lending facility was entered with Mercer Street Global Opportunity Fund, LLC.
- The new arrangement offers improved terms and greater funding flexibility.
- The refinancing extends the maturity profile of identitii’s debt.
- Previous financial covenants have been removed under the new facility.
- The refinancing strengthens identitii’s balance sheet.
- The arrangement supports identitii’s strategic focus on product commercialisation and market expansion.
- The company believes the new funding aligns better with its long-term growth initiatives.
- The announcement was made on June 5, 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ALS Limited (ALQ) ORDINARY FULLY PAID |
Industrials |
$10,841 |
ALS AGM 2025 CEO Address
|
30 Jul 2025 9:42AM |
$18.180 |
$21.360 |
risen by
17.49%
|
|
| Prescient Therapeutics Limited (PTX) ORDINARY FULLY PAID |
Health Care |
$57 |
June 2025 Quarterly Update and Appendix 4C
|
30 Jul 2025 9:41AM |
$0.045 |
$0.054 |
risen by
20%
|
|
PTX - Price-sensitive ASX Announcement
Full Release
Key Points
- Prescient Therapeutics Limited advanced clinical trials for PTX-100 and PTX-200 cancer therapies.
- Positive interim data reported from ongoing clinical trials.
- Progress achieved in the development and expansion of the OmniCAR and CellPryme platforms.
- Significant investment in research and development activities during the quarter.
- The company maintained a healthy cash balance to support its planned operations.
- Updates provided on collaborations, preclinical studies, and manufacturing activities.
- The company remains focused on the development of next-generation cancer therapies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bowen Coking Coal Limited (BCB) ORDINARY FULLY PAID |
Materials |
$8 |
Company Update and Appointment of Voluntary Administrators
|
30 Jul 2025 9:41AM |
$0.075 |
$0.075 |
fallen by
0%
|
|
| Aspermont Limited (ASP) ORDINARY FULLY PAID |
Communication Services |
$22 |
Investor Update Q3
|
30 Jul 2025 9:40AM |
$0.005 |
$1.900 |
risen by
37,900%
|
|
| Coast Entertainment Holdings Limited (CEH) ORDINARY FULLY PAID |
Consumer Discretionary |
$171 |
Update - Notification of buy-back - CEH
|
30 Jul 2025 9:40AM |
$0.370 |
$0.440 |
risen by
18.92%
|
|
| Kalamazoo Resources Limited (KZR) ORDINARY FULLY PAID |
Materials |
$52 |
Investor Presentation
|
30 Jul 2025 9:40AM |
$0.090 |
$0.165 |
risen by
83.33%
|
|
Call 1300 880 160
Start a chat
Schedule a call
